Telstar Develops High-Containment Barrier Systems for Komipharm
The systems are designed for the manufacture of oncology products and to research new biotech products.
The Technology Centre for Barrier Isolation Systems of Telstar, based in the UK, has developed two high-containment barrier systems for Komipharm Pharmaceuticals, a Korean producer of oncology products and veterinary medicines supplying the Asian market. Komipharm will use these systems, one for API sampling and the other for QC sample handling in its new facility in Cheongwon, Chungcheongbuk-do, South Korea.
The systems have been designed to provide a high level of containment to protect operators working with hazardous products during the manufacturing process of highly potent APIs. These systems will also be used in the development of vaccines by genetic technology. The containment systems run at negative pressure to the surrounding room and provide operator and environmental protection according to the standard ISO 7 classification inside the isolator.
Source: Telstar
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
